Pituitary tumors exhibit a spectrum of biology, with variable growth and hormonal behaviors. They therefore provide an opportunity to examine pathogenetic mechanisms that underlie the neoplastic ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

individuals with fibroblast growth factor receptor 2 (FGFR2) fusion/rearrangement. The single-arm, open-label registration study aims to assess the therapy’s safety, pharmacokinetics ...

Aberrant signaling by fibroblast growth factor receptors (FGFRs) drives tumor cell survival and proliferation in several cancers, making them promising therapeutic targets.

Abnormal fusion of the FGFR2 gene, encoding the fibroblast growth factor receptor 2, occurs in several types of cancer, including in up to 15% of cases of intrahepatic cholangiocarcinoma.

This disorder stems primarily from gain-of-function mutations in the fibroblast growth factor receptor 3 (FGFR3) gene, which exerts widespread effects on skeletal development, leading to disrupted ...

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck ...